Matsui Akira, Tatibana Akihiko, Suzuki Noriyuki, Hirata Masaru, Oishi Yoko, Hamaguchi Youhei, Murata Yuya, Nagayama Aiko, Iwata Yuko, Okamoto Yasushi
Department of Breast Surgery, National Hospital Organization, Tokyo Medical Center, Tokyo, Japan
Department of Breast Surgery, Kanto Central Hospital of the Mutual Aid Association of Public School Teachers, Tokyo, Japan.
Anticancer Res. 2017 Nov;37(11):6481-6488. doi: 10.21873/anticanres.12104.
Taxanes are among the key drugs for breast cancer treatment. This study aimed to evaluate the efficacy of upfront weekly nanoparticle albumin-bound paclitaxel (Nab-PTX; 100 mg/m) for human epidermal growth factor 2 (HER2)-negative breast cancer.
Patients with stage II to IV breast cancer received 12 cycles of weekly 100 mg/m Nab-PTX as first-line treatment. Preoperative chemotherapy with anthracyclines after Nab-PTX was recommended.
From 2012 to 2014, we enrolled 66 patients. The overall response rate after Nab-PTX was 59.1% [95% confidence interval(CI)=47.2% to 71.0%), 63.6% in those with hormone receptor-positive tumors, and 36.4% in those with triple-negative tumors. The pathological complete response rate at surgery was 15% (95% CI=6.1% to 24.4%). Toxicity analysis showed grade 2 peripheral neuropathy in 38 patients (57.6%), grade 2/3 leukocytopenia in 29 (43.9%) and grade 2/3 liver dysfunction in five (7.5%).
Weekly neoadjuvant Nab-PTX at 100 mg/m led to good response rates (59.1%) and was well tolerated.
紫杉烷类是乳腺癌治疗的关键药物之一。本研究旨在评估 upfront 每周一次纳米白蛋白结合型紫杉醇（Nab-PTX；100 mg/m²）治疗人表皮生长因子 2（HER2）阴性乳腺癌的疗效。
II 至 IV 期乳腺癌患者接受 12 周期每周一次 100 mg/m² Nab-PTX 作为一线治疗。推荐在 Nab-PTX 治疗后使用蒽环类药物进行术前化疗。
2012 年至 2014 年，我们纳入了 66 例患者。Nab-PTX 治疗后的总体缓解率为 59.1%[95%置信区间（CI）=47.2%至 71.0%]，激素受体阳性肿瘤患者为 63.6%，三阴性肿瘤患者为 36.4%。手术时的病理完全缓解率为 15%（95%CI=6.1%至 24.4%）。毒性分析显示，38 例患者（57.6%）出现 2 级周围神经病变，29 例（43.9%）出现 2/3 级白细胞减少，5 例（7.5%）出现 2/3 级肝功能障碍。
每周一次 100 mg/m² 的新辅助 Nab-PTX 治疗导致了良好的缓解率（59.1%），且耐受性良好。
